CIViC MCP: Integrating Large Language Models with the Clinical Interpretations of Variants in Cancer

Lars Schimmelpfennig[1,2], Quentin Cody[3], Joshua McMichael[4], Adam C. Coffman[4], Jason Saliba[4], Arpad Danos[4], Susanna Kiwala[4], Alex Wagner[5,6], Javier Sanz-Cruzado[7,8], Jake Lever[7,8,]*, Malachi Griffith[1,2,4,9,]*, Obi L. Griffith[1,2,4,9,]*

[1] Department of Medicine, Washington University School of Medicine, St. Louis, Missouri, USA

[2] Department of Genetics, Washington University School of Medicine, St. Louis, Missouri, USA,

[3] Independent Researcher, Philadelphia, PA, USA

[4] McDonnell Genome Institute, Washington University School of Medicine, St. Louis, Missouri, USA.

[5] Steve and Cindy Rasmussen Institute for Genomic Medicine, Nationwide Children's Hospital, Columbus, Ohio, USA

[6] Department of Pediatrics, The Ohio State University College of Medicine, Columbus, Ohio, USA

[7] Information Retrieval Group, School of Computing Science, University of Glasgow

[8] AI4BioMed Lab, School of Computing Science, University of Glasgow

[9] Siteman Cancer Center, Washington University School of Medicine, St. Louis, Missouri, USA.

* To whom correspondence should be addressed.

Abstract

Summary: The Clinical Interpretation of Variants in Cancer (CIViC) knowledgebase provides a

community-driven, open-source platform for discussing the biological and Clinical Significance

of molecular variants in cancer. To enable users to make complex connections between CIViC

information, we developed the CIViC Model Context Protocol (MCP) server, which allows large

language models (LLMs) to directly interface with the CIViC API through natural language,

facilitating the rapid summarization of expertly curated cancer variant interpretations.

Availability and implementation: The CIViC MCP server is detailed at

https://github.com/griffithlab/civic-mcp-server with archived code and evaluation data deposited

in Zenodo (DOI: 10.5281/zenodo.17344050). The repository is a fork of

https://github.com/QuentinCody/civic-mcp-server (QuentinCody 2025) and includes instructions

for accessing the server through the Claude desktop app and hosting it locally with GPT-5. We

also provide a Python script for directly querying the MCP server.

Supplemental information: Supplementary data are available at *Bioinformatics* online.

1. Introduction

The identification of molecular variants drives precision oncology, informing clinical decision-

making and treatment strategies. To give just one illustrative example, ALK fusion variants

occur in fewer than 5% of non-small cell lung cancers but can be targeted by kinase inhibitors,

such as crizotinib, for significant improvements in patient outcomes (Kwak *et al.* 2010). The

complex mutational landscape of cancers makes the development of molecular variant

knowledgebases critical to the goal of enabling the use of genomic information in precision

oncology. To address this, the Clinical Interpretation of Variants in Cancer (CIViC)

knowledgebase provides a community-driven, open-source platform for assessing the importance

of molecular variants in cancer (available at civicdb.org) (Griffith *et al.* 2017; Danos *et al.* 2019;

Krysiak *et al.* 2022). CIViC curates evidence items from peer☐reviewed primary literature as its

fundamental unit of information. Each item is assigned an Evidence Type that reflects the

variant's clinical or biological effect, including diagnostic, predictive, prognostic, predisposing,

oncogenic, or functional. Each Evidence Type has a corresponding Significance. For example,

predictive evidence can indicate whether a tumor is sensitive or resistant to a specific therapy.

CIViC assertions are created to summarize collections of evidence items within a specific cancer

context, adhering to recognized guidelines (Li *et al.* 2017; Horak *et al.* 2022).

LLMs provide a natural-language interface to CIViC, enabling users to discover, aggregate, and

summarize curated oncology knowledge without navigating to multiple pages. They excel at

transforming unstructured biomedical text into structured outputs through few- or zero-shot

learning and entity normalization. However, general-purpose LLMs cannot guarantee coverage

of specialized, rapidly updated resources like CIViC, and they may misinterpret CIViC's data

model, fabricating details or citations when asked for fine-grained clinical information

(Bhattacharyya *et al.*). Without API integration, LLMs fall back on unstructured web browsing,

where discoverability is gated by the performance of their search mechanism. Because CIViC's

curation is intentionally granular, captured in individual evidence items for transparency and

provenance, many users may benefit from a conversational layer that retrieves the right items

and composes succinct, well-cited answers. To provide this layer, we developed a Model Context

Protocol (MCP) server that allows LLMs to query CIViC information seamlessly and provide

detailed answers to users (Figure 1). MCP servers expose external tools and data sources through

a simple, standardized interface, enabling LLMs to issue user-guided queries and receive

structured results. In biomedicine, MCP servers are increasingly wrapping domain APIs,

databases, and literature search endpoints (Kuehl *et al.* 2025). The CIViC MCP server benefits

both new and experienced users by supporting complex, reproducible queries and rapid, citation-

rich summaries.

The CIViC MCP server leverages CIViC's public GraphQL API to facilitate user-guided

queries. The GraphQL schema makes the API straightforward for LLMs to use as objects are

explicitly linked (e.g., Evidence Item → Molecular Profile → Variant), letting models see how to

move from a clinical question to the exact fields it needs. Through introspection, the LLM reads

the schema, discovers types, fields, arguments, and deprecations, and then composes precise

queries that fetch only the necessary data. The CIViC knowledge model is highly domain-

specific, including complex concepts such as "Molecular Profiles" and "Assertions," which have

precise meanings specific to the platform and may be misinterpreted by an LLM (Krysiak *et al.*

2022). Despite GraphQL introspection, early tests revealed that Claude Sonnet 4 frequently mis-

specified types and arguments, leading to invalid or overly broad queries. While introspection

did improve reliability on later queries, where the LLM could contextualize GraphQL error

messages against the schema and refine its requests, it did not close the gap relative to predefined

tools. We circumvent this challenge in the current implementation of the CIViC MCP server by

predefining the GraphQL queries, rather than allowing an LLM to write them to ensure

reliability.

2. CIViC MCP Server

The CIViC MCP server is hosted on Cloudflare with public access (https://civic-mcp-server.larscivic.workers.dev/mcp). It exposes two tools with predefined GraphQL queries that retrieve CIViC Evidence Items or Assertions for a specified Molecular Profile name (required). Cancer type and therapy are optional filters: when provided, they further restrict results to the most relevant subset; when omitted, the server returns items associated with the given molecular profile across cancer types and therapies. Both tools respond with the URL of each evidence item/assertion when called, making it easy to verify any claims made by the LLM containing specific CIViC information. Each evidence item is also associated with a PubMed ID, which can be further inspected for validation. The JSON object returned by the MCP server also includes a definition of each CIViC field to facilitate LLM summarization.

To handle spelling differences and alternate names, the MCP server normalizes user inputs (molecular profiles, cancer types, therapies) to the closest CIViC preferred label. The preferred label is the canonical, API-recognized name used for exact matching. The MCP server scores candidates with Dice's coefficient over bigrams and selects the highest-scoring alias. We chose the Dice-Sørensen coefficient because it is fast and memory light, making it a good fit for Cloudflare Workers despite more complex matchers offering higher accuracy. The VICC Gene Normalization Service identifies gene aliases (Kuzma, Stevenson and Wagner 2025). Variant aliases are extracted from the list of curated aliases in CIViC. Cancer types and therapy aliases are extracted from the Disease Ontology and the NCI Thesaurus, respectively (Sioutos *et al.* 2007; Schriml *et al.* 2012).

2.1 Example Use Case

A user asks, "What is the clinical significance of EZH2 Y646F in follicular lymphoma?" The

LLM extracts the entities (molecular profile, disease, therapy if present) and normalizes them to

CIViC preferred labels (Figure 1). It selects the get_variant_evidence tool and supplies the

necessary parameters. The MCP server then issues a predefined GraphQL query to the CIViC

API and returns structured records: Evidence Items with fields such as evidence type,

significance, direction, disease, therapy, description, evidence level, rating, and URLs. Using this

MCP response, the LLM composes an information-rich answer with links to specific CIViC

entries and underlying publications to support the response. In this case, it summarizes the

clinical relevance, including describing several clinical trials, for EZH2 Y646F's role as an

activating mutation in follicular lymphoma (FL), a potential diagnostic biomarker for FL, and a

biomarker of sensitivity to tazemetostat.

3. Evaluation

We selected a controlled classification task: given a CIViC triplet (molecular profile, cancer

type, therapy), the LLM must determine which CIViC Evidence Types that triplet has evidence

for. Then, for each applicable type, it must assign the corresponding Significance. To assess how

effectively LLMs can retrieve and interpret current CIViC information through the MCP server,

we compared GPT-5's performance with and without the MCP server on the same set of 100

randomly selected triplets from CIViC evidence items. We used a two-step prompt at

temperature = 1 (Supplementary Prompts 1-4). GPT-5 was first prompted to identify which

Evidence Types were relevant to each triplet with a series of yes/no questions. Among the

Evidence Types identified as relevant, we prompted GPT-5 to identify each corresponding

Significance as being supported, not supported, or lacking evidence. Each triplet could have

multiple associated Evidence Types and Significances. Performance is reported at the level of

each Evidence Type, with group-level scores calculated by micro-averaging across all associated

Significance labels (Figure 1b). We excluded the common "No Evidence" label to avoid inflating

global metrics and obscuring errors. GPT-5 + MCP achieved a weighted F1-score of 94.2%.

Without the MCP server, GPT-5's performance dropped to an overall F1-score of 49.4%.

Oncogenic evidence proved most challenging for GPT-5, with an F1-score of just 9%, likely

reflecting the limited number of such examples in its pretraining data.

We also evaluated ChatGPT-5's agent mode, which crawls websites by simulating human inputs,

on ten randomly selected CIViC triplets. Agent mode achieved perfect accuracy, correctly

identifying the Clinical Significance of all ten triplets, whereas GPT-5 alone succeeded on only

four (Supplementary Table 3). We then compared response times between the MCP server and

agent mode. For 100 triplets, the MCP server had a mean latency of 3.51 seconds (95% CI: 3.34-

3.67). In contrast, agent mode required substantially longer, with a mean latency of 306 seconds

(95% CI: 132-480) across ten triplets.

4. Conclusion

We demonstrate that MCP servers provide standardized, LLM-friendly gateways to curated

biomedical databases, enabling precise retrieval and structured summarization. Connecting

CIViC to LLMs through MCP improves the accuracy of extracting Clinical Significance in

variant-disease-therapy contexts compared with using an LLM's web client, and it reduces

latency relative to agent-mode browsing while maintaining fidelity. By offering structured, real-

time access to curated oncology knowledge, the CIViC MCP server mitigates gaps in pretraining

coverage, reduces hallucination risk, and yields reproducible, citation-rich outputs. MCP-

mediated access both improves accuracy and shortens time to answer. Future work will develop

constrained query-composition methods that complement predefined tools, enabling the safe

execution of LLM-written queries to address unanticipated user questions. The CIViC MCP

server can also be extended to integrate with complementary knowledgebases (e.g., DGIdb,

ClinVar, OncoKB), enabling unified multi-database retrieval and cross-knowledge

summarization through a single conversational interface.

Figure 1. CIViC MCP workflow and evaluation. (a) Workflow. A user asks, "What is the clinical significance of EZH2 Y646F in Follicular Lymphoma?" The LLM: (1) reads the MCP manifest and tool descriptions, (2) extracts intent and named entities (molecular profile, disease, therapy), (3) selects the appropriate MCP tool, (4) fills parameters and issues a fixed-schema GraphQL query via the CIViC MCP server, (5) the MCP server queries the CIViC API and returns structured data, (6) the MCP server enriches records with concise field descriptions, (7) the LLM composes a summary. **(b) Evaluation setup.** We formed question/answer pairs from 100 CIViC triplets (molecular profile, disease, therapy). For each triplet, the model first identified which Evidence Types have CIViC evidence and then assigned the corresponding Significance label (supported, not supported, or lacking evidence). These are presented as sets of contingent questions. **(c) Classification performance.** CIViC MCP enhances precision, recall, and F1.

Author Contributions

Lars Schimmelpfennig (Formal analysis [lead], Investigation [lead], Writing-original draft [lead], Software [lead]), Quentin Cody, (Software [lead: created the original MCP server], Writing-review & editing [supporting]), Joshua McMichael (Visualization [lead]), Adam C. Coffman (Writing-review & editing [supporting]), Jason Saliba (Writing-review & editing [supporting]), Arpad Danos (Writing-review & editing [supporting]), Susanna Kiwala (Writing-review & editing [supporting]), Alex H. Wagner (Writing-review & editing [supporting]), Javier Sanz-Cruzado (Writing-review & editing [supporting]), Jake Lever (Writing-review & editing [supporting], Supervision [lead]), Malachi Griffith (Writing-review & editing [supporting], Supervision [lead]), Obi L. Griffith (Writing-review & editing [supporting], Supervision [lead]).

Conflict of interest: None declared.

Funding

This work was supported by the National Cancer Institute (NCI) of NIH award numbers U24CA237719, U24CA258115, and U24CA275783.

References

Bhattacharyya M, Miller VM, Bhattacharyya D *et al.* High Rates of Fabricated and Inaccurate References in ChatGPT-Generated Medical Content. *Cureus* **15**:e39238.

Cannon M, Stevenson J, Stahl K *et al.* DGIdb 5.0: rebuilding the drug-gene interaction database for precision medicine and drug discovery platforms. *Nucleic Acids Res* 2024;**52**:D1227–35.

Danos AM, Krysiak K, Barnell EK *et al.* Standard operating procedure for curation and clinical interpretation of variants in cancer. *Genome Med* 2019;**11**:76.

Griffith M, Spies NC, Krysiak K *et al.* CIViC is a community knowledgebase for expert crowdsourcing the clinical interpretation of variants in cancer. *Nat Genet* 2017;**49**:170–4.

Horak P, Griffith M, Danos AM *et al.* Standards for the classification of pathogenicity of somatic variants in cancer (oncogenicity): Joint recommendations of Clinical Genome Resource (ClinGen), Cancer Genomics Consortium (CGC), and Variant Interpretation for Cancer Consortium (VICC). *Genet Med Off J Am Coll Med Genet* 2022;**24**:986–98.

Krysiak K, Danos AM, Saliba J *et al.* CIViCdb 2022: evolution of an open-access cancer variant interpretation knowledgebase. *Nucleic Acids Res* 2022;**51**:D1230–41.

Kuehl M, Schaub DP, Carli F *et al.* Community-based biomedical context to unlock agentic systems. 2025:2025.07.21.665729.

Kuzma K, Stevenson J, Wagner A. VICC Gene Normalization Service. 2025, DOI: 10.5281/zenodo.16272753.

Kwak EL, Bang Y-J, Camidge DR *et al.* Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. *N Engl J Med* 2010;**363**:1693–703.

Li MM, Datto M, Duncavage EJ *et al.* Standards and Guidelines for the Interpretation and Reporting of Sequence Variants in Cancer. *J Mol Diagn JMD* 2017;**19**:4–23.

QuentinCody. QuentinCody/civic-mcp-server. 2025.

196   Schriml LM, Arze C, Nadendla S *et al.* Disease Ontology: a backbone for disease semantic
197   integration. *Nucleic Acids Res* 2012;**40**:D940–6.
198   Sioutos N, de Coronado S, Haber MW *et al.* NCI Thesaurus: a semantic model integrating
199   cancer-related clinical and molecular information. *J Biomed Inform* 2007;**40**:30–43.

```
molecularProfileName: EZH2 Y646F
diseaseName: Follicular Lymphoma
}
```

CiVIC

CiViC MCP Server Query to CiViC API

```
getEvidenceItems(molecularProfileName, diseaseName)
{
  status, significance, evidenceType, evidenceDirection,
  significance, variantOrigin, description,evidenceLevel,
  evidenceRating, source
}
```

```
query vari
{
  molecul
  disease
}
```

b LLM vs. LLM + MCP classification testing

```
Classification questions (multiple contingent series)

For EZH2 Y646F in FL with Tazemetostat, is
there predictive CiViC evidence?

Does predictive evidence of EZH2 Y646F in
FL support sensitivity to Tazemetostat?
```

Answers

Yes

Supports

```
             for each question
send question  ──────────────►           LLM answers ──►  evaluate
    ▼                                                       answers
record answer

            compare to CiViC ground truth
```